PARP inhibitor BS-201 plus chemotherapy: new option for triple-negative breast cancer

Share :
Published: 3 Jul 2009
Views: 22992
Dr Joyce O'Shaughnessy - Baylor-Charles A. Sammons Cancer Center, US
Joyce O’Shaughnessy, MD, Baylor-Charles A. Sammons Cancer Center, Dallas, Texas, speaking at ASCO 2009: PARP Inhibitor BS-201 Plus Chemotherapy May Offer New Treatment Option for Triple-Negative Breast Cancer: A randomized Phase II study, featured in ASCO’s plenary session, shows that women with metastatic triple-negative breast cancer who received the investigational PARP inhibitor BSI-201, in combination with conventional chemotherapy, lived significantly longer and experienced significantly better progression-free survival than women who received standard chemotherapy alone.